氨氯地平阿托伐他汀钙片治疗老年高血压、冠心病合并颈动脉粥样硬化患者的疗效
|
摘要
目的研究氨氯地平阿托伐他汀钙片治疗老年高血压、冠心病合并颈动脉粥样硬化患者的效果。方法抽取该院2018年1月—2019年3月进行治疗的80例老年高血压、冠心病合并颈动脉粥样硬化患者,根据治疗差异分为两组均40例,其中对照组实施氨氯地平治疗,研究组再此基础上实施阿托伐他汀钙片,对比两组患者颈动脉粥样硬化情况、血压、炎症因子。结果治疗前两组患者颈动脉粥样硬化斑块相关数据无明显区别,治疗前两组患者炎症因子,治疗前两组患者的血压无明显变化(P>0.05);治疗后研究组Crouse积分(4.11±1.69)分、IMT(0.80±0.09)mm、斑块面积(13.12±0.89)mm2、CCAD(5.38±0.16)mm均低于对照组(5.43±2.32)分、(0.89±0.11)min、(14.43±1.05)mm2、(4.35±0.25)min(t=2.909、4.005、6.019、-21.947,P=0.005、0.000、0.000、0.000);治疗后研究组炎症因子TNF-α(156.52±11.12)ng/L、IL-6(15.52±3.25)ng/L、CRP(3.98±0.88)mg/L低于对照组(209.52±12.54)ng/L、(19.47±3.41)ng/L (7.62±1.25)mg/L (t=20.000、5.303、15.060,P=0.000、0.000、0.000);治疗后研究组舒张压(72.43±7.25)mmHg、收缩压(122.43±10.32)mmHg低于对照组(88.23±9.52)mmHg、(145.34±13.11)mmHg(t=8.351、8.684,P=0.000、0.000),差异无统计学意义(P<0.05)。结论对于高血压、冠心病合并动脉粥样硬化的老年患者,可及时采取氨氯地平阿托伐他汀钙片治疗,患者血压可及时减低,并改善相关炎症因子,且颈动脉粥样硬化斑块情况有效好转,值得应用。
Objective To study the efficacy of Amlodipine Besylate/Atorvastatin Calcium in elderly hypertension and coronary heart disease(CHD) patients with carotid atherosclerosis. Methods A total of 80 elderly hypertension and CHD patients with carotid atherosclerosis treated from January 2018 to March 2019 in our hospital were selected. They were divided into control group(n=40) and study group(n=40) according to different therapies. The control group was treated with Amlodipine Besylate; the study group was treated with Amlodipine Besylate/Atorvastatin Calcium. The atherosclerosis conditions, blood pressure and inflammatory factors were compared. Results Before treatment, related parameters of carotid atherosclerosis plaque between groups were not significantly different. The difference of inflammatory factors between groups were not significantly different. Blood pressure between groups were not significantly different. After treatment, crouse scores, IMT(inteima-media thickness), plaque area and CCAD(common carotid artery diameter) in the study group were(4.11±1.69)points,(0.80±0.09)mm,(13.12±0.89)mm2 and(5.38±0.16)mm, which were lower than those in the control group [(5.43 ±2.32)points,(0.89±0.11)mm,(14.43 ±1.05)mm2,(4.35 ±0.25)mm](t =2.909,4.005, 6.019,-21.947; P=0.005, 0.000, 0.000, 0.000). After treatment, TNF-α(tumor necrosis factor-α), IL-6(interleukin-6) and CRP(C-reactive protein) contents in the study group were(156.52±11.12)ng/L,(15.52±3.25)ng/L and(3.98±0.88)mg/L, which were lower than those in the control group [(209.52±12.54)ng/L,(19.47±3.41)ng/L,(7.62±1.25)mg/L](t=20.000, 5.303, 15.060; P=0.000, 0.000, 0.000). DBP(diastolic blood pressure) and SBP(systolic blood pressure) in the study group were(72.43±7.25)mmHg and(122.43±10.32)mmHg, which were lower than those in the control group [(88.23±9.52)mmHg,(145.34±13.11)mmHg,(t=8.351, 8.684; P=0.000, 0.000). Conclusion Amlodipine Besylate/Atorvastatin Calcium can properly reduce the blood pressure, and improve relevant inflammatory factors and carotid atherosclerosis plaque conditions. It is worthy of clinical application.
Objective To study the efficacy of Amlodipine Besylate/Atorvastatin Calcium in elderly hypertension and coronary heart disease(CHD) patients with carotid atherosclerosis. Methods A total of 80 elderly hypertension and CHD patients with carotid atherosclerosis treated from January 2018 to March 2019 in our hospital were selected. They were divided into control group(n=40) and study group(n=40) according to different therapies. The control group was treated with Amlodipine Besylate; the study group was treated with Amlodipine Besylate/Atorvastatin Calcium. The atherosclerosis conditions, blood pressure and inflammatory factors were compared. Results Before treatment, related parameters of carotid atherosclerosis plaque between groups were not significantly different. The difference of inflammatory factors between groups were not significantly different. Blood pressure between groups were not significantly different. After treatment, crouse scores, IMT(inteima-media thickness), plaque area and CCAD(common carotid artery diameter) in the study group were(4.11±1.69)points,(0.80±0.09)mm,(13.12±0.89)mm2 and(5.38±0.16)mm, which were lower than those in the control group [(5.43 ±2.32)points,(0.89±0.11)mm,(14.43 ±1.05)mm2,(4.35 ±0.25)mm](t =2.909,4.005, 6.019,-21.947; P=0.005, 0.000, 0.000, 0.000). After treatment, TNF-α(tumor necrosis factor-α), IL-6(interleukin-6) and CRP(C-reactive protein) contents in the study group were(156.52±11.12)ng/L,(15.52±3.25)ng/L and(3.98±0.88)mg/L, which were lower than those in the control group [(209.52±12.54)ng/L,(19.47±3.41)ng/L,(7.62±1.25)mg/L](t=20.000, 5.303, 15.060; P=0.000, 0.000, 0.000). DBP(diastolic blood pressure) and SBP(systolic blood pressure) in the study group were(72.43±7.25)mmHg and(122.43±10.32)mmHg, which were lower than those in the control group [(88.23±9.52)mmHg,(145.34±13.11)mmHg,(t=8.351, 8.684; P=0.000, 0.000). Conclusion Amlodipine Besylate/Atorvastatin Calcium can properly reduce the blood pressure, and improve relevant inflammatory factors and carotid atherosclerosis plaque conditions. It is worthy of clinical application.
引文
[1]徐以康.阿托伐他汀联合氨氯地平对高血压冠心病的血液动力学、心电图特点及药物安全性研究[J].中国现代医生,2018,56(9):76-78,83.
[2]李莉,徐志勇,禹颖,等.麝香保心丸联合氨氯地平阿托伐他汀钙治疗高血压合并冠心病的疗效观察[J].现代药物与临床,2016,31(3):302-305.
[3]向阳,李萍,鄢学,等.阿托伐他汀联合氨氯地平早期大剂量用于高血压并急性冠脉综合征的临床评价[J].中国药业,2016,25(11):25-27,35.
[4]李玉敏.血脂康胶囊联合氨氯地平阿托伐他汀钙片治疗高血压并冠心病的临床疗效及其对血脂、血管内皮功能及炎症的影响[J].实用心脑肺血管病杂志,2016,24(7):90-93.
[5]徐炎,侯敏,高鹏,等.氨氯地平联合阿托伐他汀钙片治疗老年高血压合并冠心病患者的临床疗效及对血清Apelin、Hcy水平的影响[J].中国老年学杂志,2017,37(13):3215-3217.
[6] Leu Hsin-Bang,Chung Chia-Min,Lin Shing-Jong,et al.Association of circadian genes with diurnal blood pressure changes and non-dipper essential hypertension:a genetic association with young-onset hypertension[J].Hypertension research:Official journal of the Japanese Society of Hypertension,2015,38(2):155-162.
[7]王婷婷,李雪芹.阿托伐他汀钙片联合氨氯地平对老年冠心病合并高血压患者血清炎性因子及心率变异性的影响研究[J].国际检验医学杂志,2018,39(17):2182-2184.
[8]张丽,包成梅,尹承华,等.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病伴颈动脉粥样硬化的效果观察[J].中国基层医药,2018,25(24):3180-3184.
[9] Marra Alberto M,Egenlauf Benjamin,Ehlken Nicola,et al.Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J].International Journal of Cardiology,2015,195:19-26.
[10]万兴富,李滨.氨氯地平联合阿伐他汀钙对高血压合并高脂血症病人血小板活化功能及炎症介质的影响[J].中西医结合心脑血管病杂志,2018,16(17):2540-2542.
[11]鞠延玲,藏雪莲,赵旭,等.氨氯地平阿托伐他汀钙片对冠心病、高血压合并颈动脉粥样硬化患者的IMT、PV、TNF、CRP、血脂水平的影响[J].实用临床医药杂志,2017,21(1):14-18.
[12]曹飞,张志敏,张志琴,等.阿托伐他汀联合贝那普利、氨氯地平对非杓型高血压患者降压疗效的观察[J].中国心血管病研究,2017,15(3):273-275.
[13]杨静,李钰兰.缬沙坦氨氯地平片联合阿托伐他汀钙片治疗高血压伴高血脂的临床效果及其对血管与心肌的保护作用[J].中国慢性病预防与控制,2017,25(3):224-226.
[14]孙东升.高血压冠心病合并颈动脉粥样硬化临床应用氨氯地平阿托伐他汀钙片治疗的疗效[J].中国实用医药,2017,12(10):29-32.
[2]李莉,徐志勇,禹颖,等.麝香保心丸联合氨氯地平阿托伐他汀钙治疗高血压合并冠心病的疗效观察[J].现代药物与临床,2016,31(3):302-305.
[3]向阳,李萍,鄢学,等.阿托伐他汀联合氨氯地平早期大剂量用于高血压并急性冠脉综合征的临床评价[J].中国药业,2016,25(11):25-27,35.
[4]李玉敏.血脂康胶囊联合氨氯地平阿托伐他汀钙片治疗高血压并冠心病的临床疗效及其对血脂、血管内皮功能及炎症的影响[J].实用心脑肺血管病杂志,2016,24(7):90-93.
[5]徐炎,侯敏,高鹏,等.氨氯地平联合阿托伐他汀钙片治疗老年高血压合并冠心病患者的临床疗效及对血清Apelin、Hcy水平的影响[J].中国老年学杂志,2017,37(13):3215-3217.
[6] Leu Hsin-Bang,Chung Chia-Min,Lin Shing-Jong,et al.Association of circadian genes with diurnal blood pressure changes and non-dipper essential hypertension:a genetic association with young-onset hypertension[J].Hypertension research:Official journal of the Japanese Society of Hypertension,2015,38(2):155-162.
[7]王婷婷,李雪芹.阿托伐他汀钙片联合氨氯地平对老年冠心病合并高血压患者血清炎性因子及心率变异性的影响研究[J].国际检验医学杂志,2018,39(17):2182-2184.
[8]张丽,包成梅,尹承华,等.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病伴颈动脉粥样硬化的效果观察[J].中国基层医药,2018,25(24):3180-3184.
[9] Marra Alberto M,Egenlauf Benjamin,Ehlken Nicola,et al.Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension[J].International Journal of Cardiology,2015,195:19-26.
[10]万兴富,李滨.氨氯地平联合阿伐他汀钙对高血压合并高脂血症病人血小板活化功能及炎症介质的影响[J].中西医结合心脑血管病杂志,2018,16(17):2540-2542.
[11]鞠延玲,藏雪莲,赵旭,等.氨氯地平阿托伐他汀钙片对冠心病、高血压合并颈动脉粥样硬化患者的IMT、PV、TNF、CRP、血脂水平的影响[J].实用临床医药杂志,2017,21(1):14-18.
[12]曹飞,张志敏,张志琴,等.阿托伐他汀联合贝那普利、氨氯地平对非杓型高血压患者降压疗效的观察[J].中国心血管病研究,2017,15(3):273-275.
[13]杨静,李钰兰.缬沙坦氨氯地平片联合阿托伐他汀钙片治疗高血压伴高血脂的临床效果及其对血管与心肌的保护作用[J].中国慢性病预防与控制,2017,25(3):224-226.
[14]孙东升.高血压冠心病合并颈动脉粥样硬化临床应用氨氯地平阿托伐他汀钙片治疗的疗效[J].中国实用医药,2017,12(10):29-32.